argenx SE

374.14-0.1000-0.03%Vol 164.62K1Y Perf 19.52%
Aug 11th, 2022 16:00 DELAYED
BID325.00 ASK568.67
Open380.84 Previous Close374.24
Pre-Market- After-Market374.14
 - -  - -%
Target Price
402.73 
Analyst Rating
Strong Buy 1.25
Potential %
7.64 
Finscreener Ranking
★★★+     51.37
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
★★★+     52.76
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
★★     45.17
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Price Range Ratio 52W %
90.06 
Earnings Rating
Strong Buy
Market Cap20.60B 
Earnings Date
28th Jul 2022
Alpha0.05 Standard Deviation0.18
Beta0.92 

Today's Price Range

370.69382.03

52W Range

249.50387.89

5 Year PE Ratio Range

-48.70-32.80

Summary:

Buy

Technical Indicators: Buy
Moving Averages: Strong Buy
Performance
1 Week
1.71%
1 Month
6.18%
3 Months
28.88%
6 Months
31.26%
1 Year
19.52%
3 Years
167.68%
5 Years
1 788.64%
10 Years
-

TickerPriceChg.Chg.%
ARGX374.14-0.1000-0.03
AAPL168.49-0.7500-0.44
GOOG119.82-0.8300-0.69
MSFT287.02-2.1400-0.74
XOM93.192.62002.89
WFC45.250.92002.08
JNJ167.14-3.5300-2.07
FB196.640.99000.51
GE78.901.76002.28
JPM120.141.75001.48
 
ProfitabilityValueIndustryS&P 500US Markets
99.60
-72.40
-71.20
-481.80
-82.10
RevenueValueIndustryS&P 500US Markets
50.29M
0.93
65.76
61.03
Earnings HistoryEstimateReportedSurprise %
Q02 2022-4.76-3.8119.96
Q01 2022-5.07-4.3614.00
Q04 2021-4.88-4.762.46
Q03 2021-4.48-4.401.79
Q02 2021-3.381.98158.58
Q01 2021-3.14-0.8174.20
Q04 2020-2.89-4.20-45.33
Q03 2020-2.80-3.96-41.43
Earnings Per EndEstimateRevision %Trend
6/2022 QR-4.777.92Positive
9/2022 QR-4.905.95Positive
12/2022 FY-19.157.17Positive
12/2023 FY-17.52-1.10Negative
Next Report Date-
Estimated EPS Next Report-4.77
Estimates Count10
EPS Growth Next 5 Years %3.20
Volume Overview
Volume164.62K
Shares Outstanding55.06K
Shares Float54.24M
Trades Count7.25K
Dollar Volume61.77M
Avg. Volume237.65K
Avg. Weekly Volume170.58K
Avg. Monthly Volume251.47K
Avg. Quarterly Volume290.91K

argenx SE (NASDAQ: ARGX) stock closed at 374.14 per share at the end of the most recent trading day (a -0.03% change compared to the prior day closing price) with a volume of 164.62K shares and market capitalization of 20.60B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 188 people. argenx SE CEO is Tim Van Hauwermeiren.

The one-year performance of argenx SE stock is 19.52%, while year-to-date (YTD) performance is 6.84%. ARGX stock has a five-year performance of 1788.64%. Its 52-week range is between 249.5 and 387.89, which gives ARGX stock a 52-week price range ratio of 90.06%

argenx SE currently has a PE ratio of -31.60, a price-to-book (PB) ratio of 7.81, a price-to-sale (PS) ratio of 393.03, a price to cashflow ratio of 57.40, a PEG ratio of 2.32, a ROA of -17.83%, a ROC of -19.41% and a ROE of -19.95%. The company’s profit margin is -82.10%, its EBITDA margin is -71.20%, and its revenue ttm is $50.29 Million , which makes it $0.93 revenue per share.

Of the last four earnings reports from argenx SE, there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $-4.77 for the next earnings report. argenx SE’s next earnings report date is -.

The consensus rating of Wall Street analysts for argenx SE is Strong Buy (1.25), with a target price of $402.73, which is +7.64% compared to the current price. The earnings rating for argenx SE stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

argenx SE has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

argenx SE has a Buy technical analysis rating based on Technical Indicators (ADX : 16.33, ATR14 : 11.89, CCI20 : 119.21, Chaikin Money Flow : -0.10, MACD : 4.28, Money Flow Index : 53.45, ROC : 2.92, RSI : 39.79, STOCH (14,3) : 60.79, STOCH RSI : 1.00, UO : 54.20, Williams %R : -39.21), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of argenx SE in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
15 (83.33 %)
15 (88.24 %)
13 (86.67 %)
Moderate Buy
1 (5.56 %)
1 (5.88 %)
1 (6.67 %)
Hold
2 (11.11 %)
1 (5.88 %)
1 (6.67 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.25
Strong Buy
1.15
Strong Buy
1.17

argenx SE

argenx SE is a clinical stage biotechnology company. It is engaged in the business of developing a pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer. Its product pipeline includes product candidates such as ARGX-111, ARGX-109, ARGX-115, ARGX-112, and others. The company operates in the Netherlands, Germany, Denmark, Belgium, Switzerland, the United States, and Luxembourg. It derives the majority of its revenues from Switzerland.

CEO: Tim Van Hauwermeiren

Telephone: +31 763030488

Address: Willemstraat 5, Breda 4811 AH, , NL

Number of employees: 188

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

71%29%

Bearish Bullish

72%28%

Bearish Bullish

69%31%

TipRanks News for ARGX

Fri, 29 Jul 2022 12:38 GMT Morgan Stanley Believes Argenx Se (ARGX) Still Has Room to Grow

- TipRanks. All rights reserved.

Mon, 27 Jun 2022 10:15 GMT H.C. Wainwright Believes Argenx Se (ARGX) Still Has Room to Grow

- TipRanks. All rights reserved.

Wed, 25 May 2022 02:36 GMT Argenx Se (ARGX) Initiated with a Buy at SVB Securities

- TipRanks. All rights reserved.

Sat, 07 May 2022 03:31 GMT Argenx Se (ARGX) Receives a Buy from Robert W. Baird

- TipRanks. All rights reserved.

Fri, 06 May 2022 12:51 GMT Analysts Offer Insights on Healthcare Companies: Argenx Se (ARGX) and US Physical Therapy (USPH)

- TipRanks. All rights reserved.

Tue, 22 Mar 2022 14:35 GMT Argenx Se (ARGX) Gets a Buy Rating from JMP Securities

- TipRanks. All rights reserved.

Mon, 07 Mar 2022 16:36 GMT Analysts Offer Insights on Healthcare Companies: Argenx Se (ARGX), Ascendis Pharma (ASND) and Apellis Pharmaceuticals (APLS)

- TipRanks. All rights reserved.

Sat, 22 Jan 2022 02:15 GMT Analysts Offer Insights on Healthcare Companies: Qiagen (QGEN), Argenx Se (ARGX) and Tecan Group AG (OtherTCHBF)

- TipRanks. All rights reserved.

Thu, 20 Jan 2022 15:45 GMT Argenx Se (ARGX) Receives a Buy from JMP Securities

- TipRanks. All rights reserved.

Sun, 09 Jan 2022 02:15 GMT Argenx Se (ARGX) Receives a Buy from Kepler Capital

- TipRanks. All rights reserved.

Sat, 08 Jan 2022 12:06 GMT Analysts Offer Insights on Healthcare Companies: Argenx Se (ARGX), Atea Pharmaceuticals (AVIR) and LAVA Therapeutics (LVTX)

- TipRanks. All rights reserved.

Fri, 07 Jan 2022 18:15 GMT Argenx Se (ARGX) Received its Third Buy in a Row

- TipRanks. All rights reserved.

News

Stocktwits